The Longevity Reality Radar
46 approaches, rated by evidence.

Therapeutic plasma exchange for aging

Therapeutic plasma exchange (TPE / 'blood cleaning'). Aging itself. Reviewed Jul 2026.

A small trial lowered biological-age scores by about 1.3 years, a surrogate marker, and there is no outcome data.

Stage
Early clinical
Rung: Early human signal. First human or biomarker data. Promising, unproven.
Evidence grade
C
small trial, surrogate
Small or uncontrolled human data, or strong animal data. How grades work.

What it is

Removing and replacing blood plasma to dilute out pro-aging circulating factors — the practical descendant of 'young blood' parabiosis experiments.

The evidence

Buck Institute trial (2025): TPE lowered biological age ~1.3 years on average, and ~2.6 years when combined with IVIG. Small studies; durability and real-world benefit still being established.

What you can do today

The human evidence is early and does not support a general recommendation. If this area is relevant to you, discuss it with a clinician. Products sold in this space are not proof that it works.

Sources

No primary paper or registry record is linked for this entry yet. The evidence summary names the studies it relies on.

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Aging itself

All 17 in Aging itself.

  • Rapamycin for longevityGrade C, strong animal data. Approved drug, off-label use.Extends lifespan across many animal species, but there is no human outcome data for longevity and side effects such as poor wound healing and infection are real.
  • Acarbose for longevityGrade C, strong animal data. Approved drug, off-label use.One of the most reproducible lifespan extenders in mice, mainly in males, but there is no human longevity trial.
  • VO₂max and strength for longevityGrade B, large cohorts. Established.In large observational cohorts the top VO₂max quartile has about 4 to 5 times lower all-cause mortality than the bottom, and nothing pharmacological on this list comes close.
  • RentosertibGrade C, post-hoc biomarker. Phase 3, for lung fibrosis.Six aging clocks moved in 42 lung-fibrosis patients over 12 weeks, a design that cannot separate slowed aging from a treated lung, and no healthy-volunteer or outcome data exist.
  • Senolytics (dasatinib, quercetin, fisetin)Grade C, small human studies. Phase 1/2.Small human studies show the drugs can be given, with off-target side effects, but no durable benefit in people has been shown.
  • Partial epigenetic reprogramming (ER-100)Grade D, animal data only. Phase 1, in the eye.A first-in-human safety trial in the eye has started, but every efficacy result so far comes from animals.

Guides that cover this